采用定量动态对比增强磁共振成像联合床旁灌注体模准确评估胰腺导管腺癌治疗反应:一项初步研究
前瞻性初步研究纳入8例胰腺导管腺癌患者,于一线化疗前及开始后8±1周行DCE-MRI并同步成像三重复灌注体模作为内部参考。基于体模数据校正后,应答组K变化为73%±6%,非应答组为-0%±5%(P<0.0001),组内变异较校正前显著减小。
要点
- DCE-MRI联合灌注体模可在化疗早期定量监测胰腺导管腺癌灌注变化。
- 体模校正后应答组K变化73%±6% vs 非应答组-0%±5%,P<0.0001。
- 校正前应答组K变化69%±23% vs 非应答组-1%±41%,P=0.0247。
核心结论
- 定量DCE-MRI可测量对化疗反应良好的胰腺导管腺癌肿瘤灌注显著增加,使用灌注体模校正后数据变异性降低。
研究设计与样本
- 前瞻性初步研究,纳入8例患者(7男1女,年龄46至78岁,平均66岁),局部晚期7例、转移性1例,于一线化疗前及开始后8±1周各行一次DCE-MRI,每次同步成像小型三重复灌注体模作为定量图像分析的内部参考。
诊断标准与关键数值
- 采用扩展Tofts模型测量肿瘤灌注参数K,分别在基于体模数据校正前后评估;应答组(n=4)8周肿瘤大小变化-12%±4%,非应答组(n=4)18%±15%(P=0.0100)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to test the feasibility of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with concurrent perfusion phantom for monitoring therapeutic response in patients with pancreatic ductal adenocarcinoma (PDAC).
MATERIALS AND METHODS: A prospective pilot study was conducted with 8 patients (7 men and 1 woman) aged 46 to 78 years (mean age, 66 years). Participants had either locally advanced (n = 7) or metastatic (n = 1) PDAC, and had 2 DCE-MRI examinations: one before and one 8 ± 1 weeks after starting first-line chemotherapy. A small triplicate perfusion phantom was imaged with each patient, serving as an internal reference for accurate quantitative image analysis. Tumor perfusion was measured with K using extended Tofts model before and after phantom-based data correction. Results are presented as mean ± SD and 95% confidence intervals (CIs). Statistical difference was evaluated with 1-way analysis of variance.
RESULTS: Tumor-size change of responding group (n = 4) was -12% ± 4% at 8 weeks of therapy, while that of nonresponding group (n = 4) was 18% ± 15% (P = 0.0100). Before phantom-based data correction, the K change of responding tumors was 69% ± 23% (95% CI, 32% to 106%) at 8 weeks, whereas that of nonresponding tumors was -1% ± 41% (95% CI, -65% to 64%) (P = 0.0247). After correction, the data variation in each group was significantly reduced; the K change of responding tumors was 73% ± 6% (95% CI, 64% to 82%) compared with nonresponding tumors of -0% ± 5% (95% CI, -7% to 8%) (P < 0.0001).
CONCLUSIONS: Quantitative DCE-MRI measured the significant perfusion increase of PDAC tumors responding favorably to chemotherapy, with decreased variability after correction using a perfusion phantom.
引用
- Kim H, Morgan DE, Schexnailder P, et al. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol. 2019. PMID: 30138218. doi:10.1097/RLI.0000000000000505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。